{
  "report_rows": [
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.315B vs. cons $4.302B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.05 vs. cons $3.03",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "R&DS net new bookings",
      "prediction": "BEAT",
      "answer": "pred ~$2.80B vs. cons $2.72B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 revenue",
      "prediction": "UNCHANGED",
      "answer": "guide ~$17.15B-$17.35B vs. cons $17.296B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted EBITDA",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.975B-$4.025B vs. cons $3.998B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted diluted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.65-$12.95 vs. cons $12.81",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "R&DS demand / bookings commentary",
      "prediction": "BETTER",
      "answer": "constructive commentary vs. cons UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 maintained FY guide leaves estimates flat while the stock has already rerated",
  "day5_confidence": "LOW"
}